Intracellular and Extracellular Actions of S1P
==============================================

Sphingosine 1-phosphate is the intermediate breakdown product of the catabolism of complex SLs (**Figure [1](#F1){ref-type="fig"}**), a class of lipids characterized by a C8 carboamide alcohol backbone that was discovered in the brain in 1870 ([@B148]). S1P is present in the plasma, where it binds to ApoM on HDL particles, and serum albumin ([@B23]). This bioactive lipid is in all types of mammalian cells ([@B55]) and, systemic and local gradients of S1P are essential for immune cell homing ([@B113]; [@B109]). S1P is formed from Sph by two differently localized and regulated enzyme isoforms, SphK 1 and SphK2 ([@B97]). Although SphK1 and SphK2 catalyze the same reaction, SphK1 inhibition/gene ablation decreases blood S1P, while SphK2 inhibition/gene ablation increases blood S1P. At the cellular level, studies have shown the involvement of SphK1 in cell survival and cell growth, whereas SphK2 is rather associated with growth arrest and apoptosis ([@B95]).

![Sphingolipid metabolism, S1P receptor-activated pathways and miR involved in cardiac remodeling and functions. **(A)** S1P is synthesized from sphingosine (Sph) by the sphingosine kinases, SphK1 and SphK2 and irreversible cleaved by S1P lyase (SPL), which generates hexadecenal and phosphoethanolamine. S1P is also a substrate of specific S1P phosphatases (SPPase). Ceramide derives via the sphingomyelin cycle or *de novo* sphingolipid synthesis involving serine palmitoyl transferase (SPT), 3-keto reductase (3KR), ceramide synthase (CerS), and desaturase (DeS), and converted reversibly to sphingosine (Sph) by ceramidase (CDase), or phosphorylated to ceramide-1-phosphate (C1P) by ceramide kinase (CerK) activity. S1P produced inside the cell can be transported in the intercellular space by an ATP-binding cassette transporter named spinster homolog 2 (Spns2). As ligand, S1P acts as autocrine and paracrine factor triggering specific signaling pathways by interacting with S1P specific heterotrimeric GTP binding protein-coupled receptors (GPCR), named S1PR. Three among five subtypes of S1PRs, S1PR-1 (orange), -2 (blue), and -3 (red), are expressed in cardiomocytes, cardiac fibroblasts and procursor cardiac cells. In heart, S1PR activation leads to different cardiac effects (profibrotic, green; antifibrotic and cardioprotective, black/red). The scheme exemplifies, in accordance with the current literature, the main pathways triggered by S1PR activation leading to cardiac cell protection and extracellular matrix (ECM) remodeling. Interestingly, the expression of the key enzymes involved in sphingolipid metabolism can be regulated by microRNAs (miRs) and some of them (i.e., miR-9^9^, miR-19b^6^, miR-15^10^, and miR-29^7^) also regulate the fibrotic process by affecting extracellular matrix (ECM) remodeling through the modulation of metalloprotease (MMPs), TGF-β/TGFR and Smad protein expression. **(B)** miRNA in fibrosis. Several miRs have been described as regulators of cardiac fibrosis acting as pro-fibrotic or anti-fibrotic factors on ECM remodeling (black) and on TGFβ /Smad signaling (blue).**^1^**[@B167]. **^2^**[@B165]. **^3^**[@B149]; [@B126], [@B92]; [@B31], [@B58]. **^4^**[@B11]; [@B66]. **^5^**[@B33]. **^6^**[@B183]. **^7^**[@B160], [@B1], [@B180]. **^8^**[@B34], [@B20], [@B22], [@B106], [@B166]. **^9^**[@B91]. **^10^**[@B150]. **^11^**[@B64]. **^12^**[@B115]. **^13^**[@B10].](fphar-08-00296-g001){#F1}

Sphingosine 1-phosphate acts inside cells as a signaling molecule that regulates specific targets ([@B97]), such as PHB2, a highly conserved protein that regulates mitochondrial assembly and function, TRAF-2, which is upregulated in fibroblasts, and NF-κB, which is crucially involved in inflammatory gene regulation ([@B171]; [@B4]).

However, in response to only partially known stimuli, S1P can be transported outside the cells by a specific S1P transporter, named Spns2, and upon binding to one or more of the five subtypes of G-protein-coupled receptors (GPCRs), named S1PR1-5, it triggers many downstream signaling pathways ([@B184]; [@B78]; [@B109]) (**Table [1](#T1){ref-type="table"}**). [@B63], by a differential display method, discovered the orphan GPCR Edg-1, and successively identified as a S1PR1 receptor based on the sequence homology with LPA1/Vzg-1/Edg-2. Later, other receptors, including Edg-5 and Edg-3, followed by Edg-6 and Edg-8 (now termed S1PR2, S1PR3, S1PR4 and S1PR5), were described ([@B5], [@B6]; [@B43]).

###### 

Sphingosine 1-phosphate receptors and their intracellular signaling pathways and functions.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  S1PR                                        Knock out phenotype                                                                                                Intracellular mediators   Biological effects             Cardiac function                                                               Agonists         Antagonists      Indications                         Clinical trial
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------- ------------------------------ ------------------------------------------------------------------------------ ---------------- ---------------- ----------------------------------- ------------------------
  **S1PR1 (Edg1)**\                           Normal until E11.5 then lethal, [@B96] abnormal yolk sacs, defective blood and smooth muscle, vessels maturation   (-) AC\                   Angiogenesis\                  S1PR1 agonist:\                                                                SEW2871\         VPC23019\        Multiple Sclerosis\                 FTY720-P FDA approved\
  \                                                                                                                                                              (+) ERK,Rac,\             Lymphocytes migration\         \                                                                              FTY720-P\        VPC44116\        \                                   ACT-12880 Phase II\
  Most tissues\                                                                                                                                                  PI3K, Akt                 Cardiomyocytes survival\       Improves cardiac function following myocardial infarction\                     KRP203\          W416             \                                   ONO-4641 phase II\
  \                                                                                                                                                                                                                       \                                                                              BAF312\                           Crohn's disease\                    CS-0777 Phase I\
  **Kd (nM)** (8--20)\                                                                                                                                                                                                    S1PR1 antagonists\                                                             ACT-128800\                       \                                   CYM-5442 Phase III\
  **Coupled to:** Gαi                                                                                                                                                                                                     Stroke and ischaemic pre- and post-conditioning cardioprotection               ONO-4641                          Polymyosites and Dermatomyosites\   \
                                                                                                                                                                                                                                                                                                                                           \                                   BAF-312 Phase II\
                                                                                                                                                                                                                                                                                                                                           Lupus erythematosus                 \
                                                                                                                                                                                                                                                                                                                                                                               KRP-203 Phase III

  **S1PR2 (Edg5)**\                           Normal until 3--5 weeks, [@B81]\                                                                                   (-)AC\                    Vestibular funtion\                                                                                           Not identified   JTE013                                               
  \                                           \                                                                                                                  \                         \                                                                                                                                                                                   
  Most tissues\                               Excitability at cortical neurons, severe inner ear defects heart development                                       (+) AC, PLC p38MAPK\      Vascular tone (contraction)\                                                                                                                                                        
  \                                                                                                                                                              \                         \                                                                                                                                                                                   
  **Kd (nM**) 16--27\                                                                                                                                            Rho                       Neuronal excitability\                                                                                                                                                              
  \                                                                                                                                                                                        \                                                                                                                                                                                   
  **Coupled to:** Gα~i~, Gα~q~ et Gα~12/13~                                                                                                                                                Cardiomyocyte survival                                                                                                                                                              

  **S1PR3 (Edg3**)\                           Normal\                                                                                                            (-)AC\                    Cardiac rytm regulation\       S1PR3 antagonists\                                                             FTY720-P\        VPC23019\                                            
  \                                           \                                                                                                                  \                         \                              \                                                                              \                \                                                    
  Heart Lung Spleen Kidney\                   Smaller litter size, [@B70]\                                                                                       (+) ERK, Rac,\            Vascular tone (relaxation)\    Inhibits the S1P-mediated reduction in coronary flow in perfused rat hearts\   KRP203\          CAY1044                                              
  \                                           \                                                                                                                  \                         \                              \                                                                              \                                                                     
  Intestine\                                                                                                                                                     eNOS, PLC, Akt            Cardiomyocytes survival        Partially inhibits FTY720-induced bradycardia in rats *in vivo*                                                                                      
  \                                                                                                                                                                                                                                                                                                                                                                            
  **Kd (nM**) 23--26\                                                                                                                                                                                                                                                                                                                                                          
  \                                                                                                                                                                                                                                                                                                                                                                            
  **Coupled to:** Gαi/o, Gαq, and Gα12/13                                                                                                                                                                                                                                                                                                                                      

  **S1PR4 (Edg6)**\                           Normal, [@B49]; [@B132]\                                                                                           (+) AC, ERK, PLC, Rho     Megakaryocyte\                                                                                                FTY720-P\        Not identified                                       
  \                                           \                                                                                                                                            \                                                                                                             KRP203                                                                
  Lymphoid tissues\                                                                                                                                                                        Differentiation\                                                                                                                                                                    
  \                                                                                                                                                                                        \                                                                                                                                                                                   
  Blood cells\                                                                                                                                                                             Vascular tone (contraction)\                                                                                                                                                        
  \                                                                                                                                                                                        \                                                                                                                                                                                   
  Lung smooth muscle\                                                                                                                                                                                                                                                                                                                                                          
  \                                                                                                                                                                                                                                                                                                                                                                            
  **Kd (nM**) 12--63\                                                                                                                                                                                                                                                                                                                                                          
  \                                                                                                                                                                                                                                                                                                                                                                            
  **Coupled to:** Gα~i~ and G~1~α~2/13~\                                                                                                                                                                                                                                                                                                                                       
  \                                                                                                                                                                                                                                                                                                                                                                            

  **S1PR5 (Edg8)**\                           Normal\                                                                                                            (-) AC, ERK,\             Oligodendrocytes survival\                                                                                    FTY720-P\        Not identified   Polymyosites and Dermatomyosites    BAF-312 Phase II
  Brain Skin natural killer cells\            Aberrant natural killer cells, [@B69]                                                                              (+)JNK                    Mielinization process                                                                                         KRP203\                                                               
  \                                                                                                                                                                                                                                                                                                      BAF312                                                                
  **Kd (nM**) 2--6\                                                                                                                                                                                                                                                                                                                                                            
  **Coupled to:** Gα~i~ and Gα~12/13~                                                                                                                                                                                                                                                                                                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

S1P binds to their specific GPCRs, which activate heterotrimeric G-proteins (defined here by their α subunits) to initiate signaling cascades leading to specific biological effects and functions in cardiac tissue. Agonists and antagonists for each specific S1PR subtypes are reported together with the clinical trials in which the drug have been successfully used. AC, adenylate cyclase; Akt, serine/threonine-specific protein kinase 1; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; JNK, c-jun N-terminal kinase; PI3K, Phosphatidylinositol-4,5-bisphosphate 3-kinase; PLC, Phospholipase C; p38MAPK, p38 Mitogen activated protein kinase; Rac, Ras related monomeric GTP hydrolase; Rho GTPase, Ras homolog GTP hydrolase; Kd, dissociation constant; (+) activation; (-) inhibition; Clinical trial: FTY720 (Gilenya, Fingolimod) NCT00662649 and NCT01436643; ACT-128800 (Actelion, Ponesimod) NCT01006265; ONO-4641 (Merck/Ono paharmaceuticals, Ceralifimod) NCT01081782; CS-0777 (Daiichi Sankyo Inc.) NCT00616733; CYM-5442 (Celgene, Ozanimod) NCT02531113; BAF-312 (Novartis, Siponimod) NCT01665144 and NCT00879658; KRP-203 (Novartis) NCT01294774 US National Library of Medicine.

https://clinicaltrials.gov.

Sphingosine 1-phosphate receptors are widely expressed and specifically coupled to distinct G-proteins as reported in **Table [1](#T1){ref-type="table"}** ([@B13]; [@B78]; [@B122]). Recently, studies on the crystal structure of S1PR1 ([@B56]) have indicated that the ligand likely binds the receptor by lateral access ([@B124]). Substantial evidence has demonstrated that S1PR-mediated signaling regulates many biological processes, such as cell growth and survival, migration, and adhesion ([@B97]; [@B85]; [@B121]); thus, the impairment of the SphK/S1P/S1PR axis leads to many disorders, including inflammation, fibrosis, and cancer ([@B133], [@B134]; [@B108]; [@B122]).

Cardiac Fibrosis
================

Cardiac fibrosis is a multistep disorder, which arises due to several circumstances, such as inflammation, ischaemia and senescence. Myocardial integrity is assured throughout life by fibrotic remodeling of cardiac tissue that becomes decisive in the progression of cardiac disease, thus contributing to the high risk of mortality for this disease ([@B27]; [@B80]; [@B52]).

Fibroblasts, the major producers of cardiac ECM ([@B83]), provide the initial structural support in the neonatal heart, respond electrically to mechanical stretch and participate in the synchronization of cardiac tissue ([@B152]). In chronic conditions of ischaemia or altered oxygen tension, angiotensin-aldosterone mediated oxidative/redox stress, pro-inflammatory and pro-fibrotic factors activate circulating bone marrow-derived fibrocytes, epithelial cells and resident fibroblasts that adopt an hypersecretory myofibroblast phenotype ([@B120]; [@B158]; [@B88]). Myofibroblasts, by acting in an autocrine/paracrine manner, start to overproduce ECM. Accumulation of abundant type I/III fibrillar collagen and a variety of bioactive substances causes stiffening of the heart and decreased cardiac function ([@B52]). Among the factors involved in the initiation and progression of cardiac fibrosis, transforming growth factor β (TGF-β) and the local renin-angiotensin-aldosterone system together with other cytokines, including tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), and endothelin-1 ([@B30]; [@B14]), trigger many signaling pathways, such as Smad protein and GTP hydrolase (GTPase) activation ([@B125]; [@B169]; [@B120]; [@B89]; [@B28]; [@B170]). In cardiac matrix remodeling, other key players include the zinc-dependent matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) ([@B155]; [@B107]; [@B137]; [@B102]). Aberrant levels of different MMPs and TIMPs are highly correlated with cardiac fibrosis ([@B104]; [@B2]; [@B138]). MMP-2 and MMP-9 have distinct spatial and temporal actions in cardiovascular remodeling; MMP-2 is constitutively expressed, whereas MMP-9 is inducible ([@B102]). In addition to their role in ECM degradation, MMPs also act on non-matrix molecules, such as growth factors, allowing local induction-activation of signaling pathways which has been demonstrated after MMP-9 ablation ([@B103]). Among the TIMP isoforms (TIMP1-4) implicated in cardiac fibrosis ([@B161]), the level of TIMP1 increases in diseased hearts ([@B61]) and high levels of TIMP4 are found in parallel to inhibition of MMP-9. Modulation of ECM turnover and activation of MMPs and TIMPs are controlled by many factors, including TNF-α, TGF-β and ILs ([@B117]; [@B154]; [@B170]; [@B52]). Among these factors, the hormone peptide relaxin (RLX) is a key regulator of ECM remodeling in reproductive and non-reproductive tissues ([@B127]; [@B32]; [@B110]). Particularly, RLX inhibits pro-fibrotic cytokines (i.e., TGF-β1) and modulates the accumulation and degradation of ECM that acts on MMPs and TIMPs ([@B127]; [@B8]; [@B32]; [@B37]). Moreover, recent research has found that epigenetic factors, such as miRs play an important role in tissue remodeling by controlling MMPs and TGF-β/Smad signaling (**Figure [1](#F1){ref-type="fig"}**) ([@B19]; [@B126]; [@B29]; [@B12]). Notably, miR expression can also be regulated by MMP-9 ([@B103]). Therefore, this class of small non-coding RNAs, which inhibits gene expression by binding the 3′ UTRs of target mRNAs, can be crucial for the fibrotic process, acting as either pro-fibrotic or anti-fibrotic factors. Since dysregulation in miR expression has been reported in myocardial fibrosis ([@B51]), miRs may represent a novel therapeutic strategy to counteract the fibrotic changes that occur in cardiac diseases ([@B168]).

Role for the SphK/S1P Axis And S1PR in Cardiac Fibrosis
=======================================================

Many studies performed in cultured cells as well as in animal models have proposed that S1P possesses cardioprotective effects ([@B86]; [@B72]; [@B179]; [@B73]; [@B98]). In fact, S1P protects cultured rat neonatal cardiomyocytes from ischaemia-induced cell death ([@B74]; [@B72]). Moreover, mice lacking the enzyme SPL that degrades S1P show reduced sensitivity to ischaemia/reperfusion injury and increased S1P level in both plasma and cardiac tissue ([@B71]) (**Figure [1](#F1){ref-type="fig"}**).

Regarding cardiac fibrosis, SphK1 appears to play a relevant role. SphK1 is induced by TGF-β and mediates TIMP-1 upregulation, and siRNA against SphK1 inhibited TGF-β-stimulated collagen production ([@B175]; [@B41]). Importantly, the neutralization of extracellular S1P with a specific anti-S1P antibody significantly reduced TGF-β-stimulated collagen production, indicating the involvement of an "inside-out" signaling of S1P after SphK1 activation in the pro-fibrotic action ([@B41]). Moreover, apelin, an adipocyte-derived factor, inhibits TGF-β-stimulated activation of cardiac fibroblasts by reducing SphK1 activity ([@B118]).

Notably, high S1P production/accumulation in cells is deleterious. In fact, transgenic mice that overexpressed SphK1 at high level develop spontaneous cardiomyocyte degeneration and fibrosis ([@B146]; [@B142]) and are characterized by increased levels of Rho GTPases and phospho-Smad3, suggesting that these pathways are downstream of SphK1/S1P.

Recently, we have reported that SL metabolism can be activated by RLX at concentrations similar to those previously reported to elicit specific responses in cardiac muscle cells ([@B159]). In both neonatal cardiac cells and H9C2 cells, RLX induces the activation of SphK1 and S1P production. The silencing and pharmacological inhibition of SphK1 alters the ratio MMPs/TIMPs, and CTGF expression elicited by RLX indicates that hormone peptides promote an ECM-remodeling phenotype through the activation of endogenous S1P production and SM metabolism ([@B37]).

The role of SphK2 in heart tissue is less clear. Previous research has shown that maternal-zygotic SphK2 is fundamental for cardiac development in zebrafish ([@B62]). Moreover, SphK2 knockout sensitizes mouse myocardium to ischaemia/reoxygenation injury ([@B163]), and mitochondria obtained from Sphk2 knockout mice exhibit decreased oxidative phosphorylation and increased susceptibility to permeability transition, suggesting a role as protective agent ([@B45]). SphK2 appears to be less involved in tissue fibrosis than SphK1 ([@B134]). For example, protein expression of SphK1, but not SphK2, was significantly elevated in lung tissues from patients with idiopathic pulmonary fibrosis ([@B65]). Presently, the role of SphK2 in cardiac fibrosis is still unclear. Interestingly, [@B53] have found that SphK2 is associated with histone H3, and endogenous S1P that is formed in the nucleus via SphK2 inhibits the action of HDACs ([@B53]; [@B67]). Since HDAC activity is increased in patients with cardiac fibrosis ([@B94]; [@B116]), there is a potential link between SphK2, nuclear S1P and the epigenetic regulation of gene expression that is involved in cardiac fibrosis.

Very recently, a strict correlation between the levels of miRs involved in cardiac fibrosis and SL metabolism has been demonstrated. In fact, SphK, SPT, acid SMase and ceramide synthase 6 (CerS6) can be regulated by several miRs (**Figure [1](#F1){ref-type="fig"}**). miR-613 and miR-124 inhibit SphK1 ([@B177]; [@B182]). miR-137, miR-181c, miR-9, and miR-29 regulate SPT ([@B40]). miR-15a modulates acidic SMase ([@B165]), and miR-101a targets Cer6 ([@B140]) (**Figure [1](#F1){ref-type="fig"}**). Interestingly, miR release into exosome particles depends on the ceramide-dependent pathway ([@B82]).

Although the importance of SphK/S1P system has been thoroughly reported, very little is known about the S1P/S1PR axis in the context of cardiac fibrosis. Given that specific anti-S1P antibodies significantly reduce TGF-β-stimulated collagen production by interfering with the binding of exogenous S1P to its specific receptors, a few years ago, the role of "inside-out" S1P signaling in the fibrotic process was proposed ([@B41]). Three of the five S1PRs (S1PR-1, -2, -3) are the major subtypes expressed in the heart ([@B119]; [@B100]). Major candidates for the exogenous S1P-mediated control of the fibrotic process are S1PR2 and S1PR3 ([@B145], [@B142], [@B144]) that preferentially mediate the two following parallel signaling pathways crucially involved in the fibrotic process: Ras homolog GTPase/Rho-associated-protein kinase (Rho/ROCK) and Smad proteins. Particularly, S1PR3 promotes the activation of Rho signaling and the transactivation of TGF-β ([@B147]; [@B142]). Under chronic activation of SphK1/S1P signaling, S1PR3 mediates pathological cardiac remodeling through ROS production ([@B142]). Moreover, S1PR3-mediated Akt activation protects against *in vivo* myocardial ischaemia-reperfusion ([@B101]). Characterization of S1PR3-deficient mice also indicates that HDL and S1P promote cardiac protection through nitric oxide/S1PR3 signaling, and exogenous S1P induces intracellular calcium increase through the S1PR3/PLC axis ([@B147]; [@B39]).

Furthermore, S1PR3 can mediate cardioprotection in Langendorff-perfused mouse hearts against ischaemia/reperfusion injury via Rho/NFkB signaling ([@B178]). Although, S1PR3 is the most prevalent subtype in cardiac fibroblasts ([@B144]), myofibroblast differentiation and collagen production are mainly mediated by S1PR2 signaling ([@B133]). In fact, the silencing of S1PR2, but not of S1PR1 or S1PR3, can block S1P-mediated α-SMA induction ([@B41]), and S1PR2 knock out mice show reduced fibrosis markers expression ([@B68]).

In the heart, the signaling pathways downstream of S1PR1 inhibit cAMP formation and antagonize adrenergic-mediated contractility activation ([@B100]). Through S1PR1, S1P induces hypertrophy of cardiomyocytes *in vitro* ([@B123]) and decreases vascular permeability ([@B17]). In bleomycin-induced injury, S1PR1 functional antagonists increase the pro-fibrotic response ([@B135]), suggesting an antifibrotic action of S1PR1 in the lung tissue.

There is evidence showing that S1P exhibits cross-talk with pro-fibrotic signaling pathways, such as TGF-β ([@B174]) and PDGF ([@B3]). The involvement of S1PRs in the pro-fibrotic effects that are mediated by the cross-talk between S1P and TGF-β has been demonstrated by inhibition of this effect in primary cardiac fibroblasts by the murine anti-S1P antibody, Sphingomab ([@B41]). Specifically, the role of S1PR3 has been reported in the transactivation of the TGF-β/small GTPases system ([@B143]; [@B16]). Evidence has also been provided by a study in which the S1PR1 agonists FTY720 mimicked TGF-β action by promoting the differentiation of fibroblasts to myofibroblasts, but failed to act on S1PR3^-/-^ fibroblasts ([@B76]). Differently from TGF-β, S1P and FTY720-P do not promote Smad signaling to induce ECM synthesis but rather activate PI3K/Akt and ERK1/2 ([@B136]). Moreover, TGF-β2 stimulates the transactivation of S1PR2 in cardiac fibroblasts, and the silencing of TGF-β receptor II or co-Smad4 reduces the upregulation of CTGF expression induced by FTY720-P in mesangial cells ([@B173]).

Recently, our group has demonstrated that extracellular S1P inhibits the effects of RLX on MMP-9 release and potentiates hormone action on CTGF expression and TIMP-1 expression through a S1PR subtype-mediated signaling ([@B37]). Although the action of RLX on S1PRs expression is unknown, a transactivation between S1PRs and the RLX-specific receptor RXFP1 is worthy of investigation ([@B9]).

MicroRNAs can regulate S1PRs in several pathological conditions; for example, S1PR1 expression is upregulated by the deregulation of miR-148a, leading to TGF-β-dependent epithelial-mesenchymal transition ([@B59]). TNF-α significantly increases S1PR2 expression in human endothelial cells by reducing miR-130a level ([@B35]). No data are currently available on the role of miRs that are involved in cardiac fibrosis and S1PR expression.

S1PR Modulators in Cardiac Functions
====================================

S1PR1 Agonists
--------------

**Fingolimod (FTY729),** synthesized from myriocin, is an immunosuppressive product isolated from *Isaria sinclairii* and has received approval from the Food and Drug Administration and from the European Medicines Agency as a drug for the treatment of MS (Gilenya, Novartis) ([@B25]; [@B24]; [@B26]). The phosphorylated form, phospho-FTY720 **(FTY720-P)** that is formed by SphK2 *in vivo* ([@B15]), is a structural analog of S1P that binds and activates S1PR1-3-4-5, but not S1PR2. Notably, the long-term activation of S1PR1 by FTY720-P determines receptor internalization and degradation, thus acting as a S1PR1 antagonist ([@B48]; [@B99]; [@B15]; [@B46]). Due to the binding to various S1PRs, FTY720-P is responsible for several collateral effects on MS patients, such as cardiac effects (bradycardia and atrioventricular block) ([@B128]; [@B18]; [@B44]). Such effects have been attributed to the activation of S1PR3, and in some cases, to S1PR1. Long-term S1PR1 down-regulation contributes to the disruption of Ca^2+^ homeostasis and attenuation of ischaemic preconditioning ([@B77]).

The phosphorylated form of Fingolimod takes part in cardioprotection in heart transplantation related ischaemia-reperfusion (*I/R*) injury ([@B130]) and acting as potent anti-inflammatory ([@B7]) and anti-oxidant agents may lead to reduce myocardial damage as a consequence of reduced cardiomyocytes death.

A new selective S1PR modulator, **ceralifimod (ONO-4641)**, has been recently designed and tested for its ability to limit the cardiovascular complications of Fingolimod ([@B84]). Similarly, **Amiselimod (MT-1303)**, a second-generation S1PR modulator, has potent selectivity for S1PR1 and S1PR5 and has almost fivefold weaker GIRK activation (G-protein-coupled inwardly rectifying potassium channel) than FTY720-P ([@B139]). Other interesting compounds that can act on cardiac functions have been reviewed elsewhere ([@B156]; [@B50]; [@B172]) (**Table [1](#T1){ref-type="table"}**). **SEW2871** is structurally unrelated to S1P, and its phosphorylation is not required for binding to S1PR1. SEW2871 promotes lymphopenia by reducing inflammatory cells, especially CD4^+^ T cells ([@B93]), attenuates kidney ischaemia/reperfusion injury ([@B87]), and improves cardiac functions following myocardial infarction ([@B176]). However, some evidence has indicated that SEW2871 can exacerbate reperfusion arrhythmias ([@B153]). SEW2871 and **AUY954,** an aminocarboxylate analog of FTY720 ([@B181]), directly prevent allograft rejection in rat cardiac transplantation through the regulation of lymphocyte trafficking ([@B114]). Moreover, AUY954 significantly inhibited expressions of IL-17 and MMP-9 in rat sciatic nerves ([@B181]). Repeated AUY954 administration enhanced pulmonary fibrosis by inducing vascular leak ([@B135]), suggesting caution in the use of this drug. **CYM-5442,** which binds to S1PR1 in a structural hydrophobic pocket different from Fingolimod ([@B47]), induces lymphopenia and promotes eNOS activation in endothelial cells, thus playing a role in vascular homeostasis ([@B151]). **Compound 6d** lacks S1PR3 agonism and induces lymphopenia with reduced collateral effects on the heart ([@B54]). **BAF-312** is a next-generation S1PR modulator, which is selective for S1PR1 and S1PR5 ([@B38]), and has species-specific effects on the heart. BAF-312 induces rapid and transient bradycardia in humans through GIRK activation ([@B42]). Notably, different doses may be used to limit cardiac effects ([@B90]). **KRP-203** reduced chronic rejection and graft vasculopathy in rat skin and heart allografts ([@B141]), and in an experimental autoimmune myocarditis model, it significantly inhibited the infiltration of immune cells into the myocardium, reducing the area of inflammation ([@B111]). Currently, KRP-203 is undergoing a clinical trial for subacute lupus erythaematosus and in patients undergoing stem cell transplantation for hematological malignancies.

**S1PR1 antagonists** were reported to have therapeutic potential, but their use requires attention. **VPC23019,** acting as S1PR1 and S1PR3 antagonist, has been used in ischaemic pre- and post-conditioning cardioprotection that is promoted by endogenous S1P in *ex vivo* rat hearts ([@B162]). **W-146,** which was initially reported to increase the basal leakage of the pulmonary endothelium ([@B129]), has been used to demonstrate the role of the S1P pathway in TGF-β1-induced expression of α-SMA in human fetal lung fibroblasts ([@B75]).

S1PR2 Agonists
--------------

S1PR2 agonists are mainly used in the treatment of hearing loss (**Table [1](#T1){ref-type="table"}**). A study has shown that **CYM-5478** has vascular effects, which is indicated by enhanced ischaemia-reperfusion injury *in vivo* ([@B131]).

S1PR2 Antagonists
-----------------

**JTE-013** was initially reported to affect coronary artery contraction ([@B112]). At long-term S1PR2 antagonism induces several collateral effects, such as a high incidence of B cell lymphoma ([@B21]).

S1PR3 Antagonists
-----------------

Selectively blocking S1PR3 is very difficult. For example, **VPC25239** antagonizes both S1PR3 and S1PR1, affecting smooth muscle cell functions, whereas VPC01091 leads to neointimal hyperplasia by preferentially blocking S1PR3 ([@B164]). Other antagonists for S1PR3 are as follows: **CAY10444 (or BML-241)** ([@B79]) that can inhibit the prosurvival effect of HDLs after hypoxia-reoxygenation and **TY-52156** that suppresses the bradycardia induced by FTY-720 *in vivo* and promotes vascular contraction ([@B105]).

The therapeutic use of monoclonal antibodies can be a valid alternative to synthetic compounds. A **monoclonal antibody, 7H9,** functionally blocks S1PR3 activation both *in vitro* and *in vivo* ([@B60]), reduces the growth of breast cancer tumors and prevents systemic inflammation, representing an effective approach against the morbidity of sepsis ([@B57]). To date, no specific antagonists for S1PR4 and S1PR5 are available, although (*S*)-FTY720-vinylphosphonate acts as a pan-antagonist that fully antagonizes S1PR1, S1PR3 and S1PR4 and partially antagonizes S1PR2 and S1PR5 ([@B157]).

Conclusion
==========

Targeting S1P signaling might be an intriguing new strategy for the treatment of cardiac fibrosis. However, the double face of the "sphinx" should be carefully considered, and the potential of the multiple collateral effects of S1PR modulators should be evaluated with caution.
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3KR

:   3-keto reductase

AC

:   adenylate cyclase

Akt

:   serine/threonine-specific protein kinase 1

ApoM

:   apolipoprotein M

C1P

:   ceramide-1-phosphate

cAMP

:   cyclic adenosine monophosphate

CDase

:   ceramidase

Cer

:   ceramide

CerK

:   ceramide kinase

CerS

:   ceramide synthase

CTGF

:   connective tissue growth factor

DeS

:   desaturase

ECM

:   extracellular matrix

Edg-1

:   endothelial differentiation gene-1

eNOS

:   endothelial nitric oxide synthase

ERK1/2

:   extracellular signal-regulated kinase 1/2

GIRK

:   G protein-coupled inwardly rectifying potassium channels

GPCR

:   G-protein coupled receptors

GTP

:   guanosine triphosphate

HDAC

:   histone deacetylase

HDL

:   high density lipoproteins

IL

:   interleukin

LPA1

:   lysophosphatidic acid receptor 1

miR

:   microRNA

MMP

:   matrix metalloproteinase

MS

:   multiple sclerosis

NF-κB

:   nuclear factor kappa-light-chain-enhancer of activated B cell

PDGF

:   platelet-derived growth factor

PHB2

:   prohibitin 2

PI3K

:   phosphatidylinositol-4,5-bisphosphate 3-kinase

PLC

:   phospholipase C

Rho GTPase

:   Ras homolog GTP hydrolase

RLX

:   relaxin

ROCK

:   Rho associated-protein kinase

RXFP1

:   relaxin/insulin like family peptide receptor 1

S1P

:   sphingosine 1-phosphate

S1PR

:   S1P receptor

siRNA

:   short interfering RNA

SL

:   sphingolipid

SM

:   sphingomyelin

SMA

:   smooth muscle actin

Smad

:   small mother aganist decapentaplegic

SMase

:   sphingomyelinase

SMS

:   sphingomyelin synthase

Sph

:   sphingosine

SphK

:   sphingosine kinase

SPL

:   S1P lyase

Spns2

:   Spinster 2 (S1P transporter)

SPPase

:   S1P phosphatases

SPT

:   serine palmitoyl transferase

TGFBR

:   TGF receptor

TGFβ

:   transforming growth factor β

TIMP

:   tissue inhibitors of metalloproteinase

TNF

:   tumor necrosis factor

TRAF-2

:   TNF receptor-associated factor 2

UTR

:   untranslated region

Vzg-1

:   ventricular zone gene-1.
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